SPOTLIGHT -
Clinical Pearls for the Management of MS
Expert neurologists emphasize the importance of conversations around patient lifestyle, mental health, and comorbid conditions as keys to improve care for MS.
MS Diagnosis and Management Going Forward
Barry A. Hendin, MD; Regina Berkovich, MD, PhD; and Ahmed Z. Obeidat, MD, PhD, explore the role of biomarkers, precision medicine, and repair mechanisms to improve treatment of MS going forward.
Future of MS With BTK Inhibitors
Regina Berkovich, MD, PhD, and Barry A. Hendin, MD, review potential use of BTK inhibitors in the treatment of MS.
AAN Expert Exchange: Sphingosine-1 Phosphate Modulation in MS
A trio of experts in multiple sclerosis exchanges their thoughts on the use of the sphingosine-1 phosphate modulating class of medicines in treating the disease. [WATCH TIME: 3 minutes]
AAN Expert Exchange: Advances in Progressive Multiple Sclerosis
A trio of experts in multiple sclerosis exchanges their thoughts on the gains that have been made in the understanding of the progressive phases of the disease. [WATCH TIME: 3 minutes]
AAN Expert Exchange: Patient-Reported Outcomes in Multiple Sclerosis
A trio of experts in multiple sclerosis exchanges their thoughts on the importance of patient-reported outcomes in the management of patients with the disease. [WATCH TIME: 3 minutes]
Managing MS in the COVID-19 Era
Expert neurologists comment on the impact of COVID-19 on telemedicine and MS treatment selection.
VELOCE Study in Relapsing MS
Clinical implications from VELOCE, a phase 3b study examining the effect of ocrelizumab on immune responses in patients with relapsing MS.
Response to COVID-19 Vaccines in Patients Treated With High Efficacy DMTs
Dr Regina Berkovich evaluates the use of mRNA COVID-19 vaccines in patients treated with high efficacy disease-modifying therapies for MS.
Guidance on COVID-19 Vaccines for Patients With MS
Barry A. Hendin, MD, reviews guidance on COVID-19 vaccines for patients with MS, including highlights from the AAN position statement.
Treating Smoldering Inflammation in MS
Drs Barry A. Hendin and Regina Berkovich comment on the management and treatment of chronic smoldering inflammation with high efficacy therapies.
Updates From ACTRIMS 2022 for Relapsing MS
Regina Berkovich, MD, PhD, and Barry A. Hendin, MD, review clinical implications of real-world data on the use of cladribine and other DMTs in patients with relapsing MS that were presented at ACTRIMS 2022.
Considerations for Using High-Efficacy Therapy in MS
Expert neurologists discuss factors guiding their choice of high-efficacy therapy in multiple sclerosis.
Use of High-Efficacy Therapy in MS in Clinical Practice
Regina Berkovich, MD, PhD, shares her approach to selecting high-efficacy therapies in clinical practice for patients with multiple sclerosis.
Role of High Efficacy Therapy for MS
Dr Barry A. Hendin reviews the use of high efficacy therapy in MS.
Role of Inflammation in MS
Regina Berkovich, MD, PhD, defines inflammation in multiple sclerosis and its role in MS pathogenesis.
Innate and Adaptive Immunity and BTK Inhibitors for Multiple Sclerosis
Barry A. Hendin, MD, discusses innate and adaptive immunity and BTK inhibitors in the treatment of multiple sclerosis (MS).
Innate vs Adaptive Immunity in MS Management
Barry A. Hendin, MD, and Regina Berkovich, MD, PhD, provide an overview of the immune system, focusing on innate vs adaptive immunity, in the management of multiple sclerosis.
Differentiating Treatment Regimens Based on Diagnosis vs Personal Needs: Barry Hendin, MD
The neurologist from Banner Health and chief medical officer of the MS Association of America discussed how much a patients prognosis plays into the treatments utilized.
Induction Versus Escalation to Treat MS: Barry Hendin, MD
The neurologist from Banner Health and chief medical officer of the MS Association of America discussed the ongoing debate of when to administer high efficacy treatments throughout the MS disease progression.
Long-Term Changes, Strides Made in MS Care: Barry Hendin, MD
The neurologist from Banner Health and chief medical officer of the MS Association of America detailed the significant changes to the state of multiple sclerosis care over the past 3 decades.
The Significance of World MS Day: Barry Hendin, MD
The neurologist from Banner Health and chief medical officer of the MS Association of America provided perspective on the global impact World MS Day can have on the patient and clinician community.